Moreover, canagliflozin, an SGLT2 inhibitor, reduced the risk of kidney failure as well as cardiovascular events compared to the placebo group for T2DM patients with albuminuric chronic kidney disease, followed up for a median of 2.62 years [25]. This evidence concerns the gene SLC5A2 and kidney failure.